EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›EYPT

EYPT

EyePoint, Inc.

Next earnings Aug 4, 2026 · consensus $-0.97 EPS, $416K rev

Last earnings -2.9% on 2026-05-06

Avoid
$13.66
▼ -0.36%
$13.66▲ +64.98%
over 1Y
L $8.28EODHDH $18.85
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.4%
1W-0.5%
1M+3.8%
3M+9.3%
YTD-21.9%
1Y+65.0%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Avoid
Quality
F
Valuation
Fair value
Filings
Watch
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 18 analysts
Buy

Conservative balance sheet (liabilities/equity 0.19x); but revenue fell -27.5% YoY.

Revenue (FY2025) $31.4M · FY2025

EyePoint, Inc. shows $31.4M in FY2025 revenue (-27.5% YoY), a -739.4% net margin, and -75.8% ROE.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$36.9M$41.4M$46.0M$43.3M$31.4M
Gross profit—————
Operating income-$55.3M-$99.6M-$75.1M-$146M-$243M
Net income-$58.4M-$102M-$70.8M-$131M-$232M
Diluted EPS-$2.03-$2.74-$1.82-$2.32-$3.17
Net margin-158.1%-247.0%-153.8%-302.4%-739.4%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$1.07B
EV / EBITDA—
EV / Sales34.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-20.4%
FCF yield-21.4%

Quality & risk

ROIC (est.)-57.3%
Free cash flow-$243M
Total debt$29.3M
Net cash$72.5M
Altman Z-Score6.40 safe
Piotroski F-Score2/8

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+21.4%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Officer / director change2026-06-22
  2. 8-K Other event2026-05-14
  3. 10-Q Quarterly report2026-05-07
  4. 8-K Earnings results2026-05-06
  5. DEF 14A Proxy statement2026-04-27
  6. 8-K Other event2026-04-13
  7. 8-K Reg FD disclosure2026-03-20
  8. 10-K Annual report2026-03-05
  9. 8-K Earnings results2026-03-04

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-06-182026-06-22open ↗SCHEDULE 13GFiling2026-06-03open ↗4Period ending 2026-05-252026-05-27open ↗SCHEDULE 13G/AFiling2026-05-15open ↗8-KPeriod ending 2026-05-142026-05-14open ↗SCHEDULE 13G/AFiling2026-05-13open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-062026-05-06open ↗DEFA14AFiling2026-04-27open ↗DEF 14APeriod ending 2026-06-182026-04-27open ↗4Period ending 2026-04-172026-04-20open ↗144Filing2026-04-17open ↗

Quality score

F
ValueGrowthProfitHealthMom.
ValueF
GrowthF
ProfitabilityF
Financial healthB-
Momentum—
  • ✗Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
Revenue
$31.4M
-27.5% YoY
Net margin
-739.4%
ROE
-75.8%
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$31.4M-27.5%
Net income-$232M-77.2%
Operating income-$243M-66.9%
Diluted EPS-$3.17-36.6%
Cash & equivalents$102M+2.1%
Total assets$364M-13.0%
Total liabilities$57.9M-29.4%
Stockholders' equity$306M-9.0%
Op.: -776.0%L/E: 0.19x

Frequently asked

Is EyePoint, Inc. (EYPT) a buy?
EYPT currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.19x); but revenue fell -27.5% YoY.
What is EyePoint, Inc.'s quality score?
EYPT scores 31/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001314102, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 6:13:47 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 0 open-market buys · 1 sale

2026-05-25
Elston George
Chief Financial Officer
Exercise7.50K
2026-05-25
Elston George
Chief Financial Officer
Tax3.63K @ $12.93$46.9K
2026-04-17
Ribeiro Ramiro
Chief Medical Officer
Exercise2.44K @ $8.26$20.1K
2026-04-17
Ribeiro Ramiro
Chief Medical Officer
Sell2.44K @ $15.00$36.6K
2026-03-23
Duker Jay S.
President and CEO
Disposed (J)76.8K @ $13.11$1.01M
2026-03-23
Duker Jay S.
President and CEO
Acquired (J)76.8K @ $13.11$1.01M
2026-03-16
Duker Jay S.
President and CEO
Buy1.50K @ $13.15$19.7K
2026-03-04
Ribeiro Ramiro
Chief Medical Officer
Exercise2.44K @ $8.26$20.1K
2026-03-04
Ribeiro Ramiro
Chief Medical Officer
Sell2.44K @ $17.87$43.6K
2026-03-02
Elston George
Chief Financial Officer
Gift5.00K
2026-03-02
Elston George
Chief Financial Officer
Gift5.00K
2026-02-17
Ribeiro Ramiro
Chief Medical Officer
Exercise2.44K @ $8.26$20.1K

Earnings history

beat/miss · move
2026-05-06Miss -20.1% est▼ -2.91%8-K ↗
2026-03-04Miss -6.2% est▼ -1.75%8-K ↗
2026-01-07Miss -6.2% est▲ +3.02%8-K ↗
2025-11-05Miss -6.2% est▼ -11.10%8-K ↗
2025-10-14Miss -6.2% est▼ -1.35%8-K ↗
2025-08-06Miss -4.6% est▼ -2.85%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last QuarterBullish
finance.yahoo.com· 2026-05-17
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million MoreBullish
finance.yahoo.com· 2026-05-17
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million MoreBullish
nasdaq.com· 2026-05-17
EyePoint Pharmaceuticals Q1 2026 Earnings PreviewBearish
seekingalpha.com· 2026-05-05
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?Bullish
nasdaq.com· 2026-04-02
EyePoint sues Ocular over claims related to lead assetBearish
seekingalpha.com· 2026-03-21

Vs tracked universe

compare →

1044 tracked peers · median

EDGAR Score31 vs 67
Revenue growth-27.5% vs 7.1%
Net margin-739.4% vs 10.5%
Return on equity-75.8% vs 12.3%
P/E— vs 25.5

News sentiment

EODHD · 2d
Bearish
-0.68
vs typical · 4 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.